Medytox is growing as the No. 1 medical aesthetic company.

Botulinum Toxin Type A Product Meditoxin® (Neuronox)

Neuronox® 50U
Neuronox® 50U
Neuronox® 100U
Neuronox® 100U
Neuronox® 150U
Neuronox® 150U
Neuronox® 200U
Neuronox® 200U
Botulinum Toxin Type A Product Meditoxin® (Neuronox)
Botulinum Toxin Type A Product Meditoxin® (Neuronox)
Botulinum Toxin Type A Product Meditoxin® (Neuronox)
Botulinum Toxin Type A Product Meditoxin® (Neuronox)
  • Active Ingredient
    • Clostridium botulinum toxin type A (Hall group)
  • Description
    • a lyophilized white power for injection in a colorless transparent vial
  • Storage Condition
    • freeze (below -5℃) or keep refrigerated (2 - 8℃)
  • Package Unit
    • 1 vial
  • Expiry Date
    • 36 months from the manufacturing date
  • Indication and Usage
    • Benign essential blepharospasm in adults aged 18 or more
    • To treat foot deformities due to spasticity in pediatric cerebral palsy patients aged 2 or older
    • To temporarily improve moderate to severe glabellar lines related to eyebrow wrinkle muscle (corrugator muscle) and/or procerus muscle activity in adults aged from 20 to 65.
    • Muscle spasticity: upper limb local muscle spasticity related to stroke in adults aged 20 or more.
  • Active Ingredient
    • Clostridium botulinum type A (Hall group)
  • Description
    • a lyophilized white power for injection in a colorless transparent vial
  • Storage Condition
    • freeze (below -5℃) or keep refrigerated (2 - 8℃)
  • Package Unit
    • 1 vial
  • Expiry Date
    • 36 months from the manufacturing date
  • Indication and Usage
    • Benign essential blepharospasm in adults aged 18 or more
    • To treat foot deformities due to spasticity in pediatric cerebral palsy patients aged 2 or older
    • To temporarily improve moderate to severe glabellar wrinkles related to eyebrow wrinkle muscle (corrugator muscle) and/or procerus muscle activity in adults aged from 20 to 65.
    • Muscle spasticity: upper limb local muscle spasticity related to stroke in adults aged 20 or more.
  • Active Ingredient
    • Clostridium botulinum type A (Hall group)
  • Description
    • a lyophilized white power for injection in a colorless transparent vial
  • Storage Condition
    • freeze (below -5℃) or keep refrigerated (2 - 8℃)
  • Package Unit
    • 1 vial
  • Expiry Date
    • 36 months from the manufacturing date
  • Indication and Usage
    • Benign essential blepharospasm in adults aged 18 or more
    • To treat foot deformities due to spasticity in pediatric cerebral palsy patients aged 2 or older
    • To temporarily improve moderate to severe glabellar wrinkles related to eyebrow wrinkle muscle (corrugator muscle) and/or procerus muscle activity in adults aged from 20 to 65.
    • Muscle spasticity: upper limb local muscle spasticity related to stroke in adults aged 20 or more.
  • Active Ingredient
    • Clostridium botulinum type A (Hall group)
  • Description
    • a lyophilized white power for injection in a colorless transparent vial
  • Storage Condition
    • freeze (below -5℃) or keep refrigerated (2 - 8℃)
  • Package Unit
    • 1 vial
  • Expiry Date
    • 36 months from the manufacturing date
  • Indication and Usage
    • Benign essential blepharospasm in adults aged 18 or more
    • To treat foot deformities due to spasticity in pediatric cerebral palsy patients aged 2 or older
    • To temporarily improve moderate to severe glabellar wrinkles related to eyebrow wrinkle muscle (corrugator muscle) and/or procerus muscle activity in adults aged from 20 to 65.
    • Muscle spasticity: upper limb local muscle spasticity related to stroke in adults aged 20 or more.
제품 변경사항You can find the recent approval updates and detailed medical device information on Emed (http://emed.mfds.go.kr) → [Information] → [product information].